Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

14.3%

1 terminated/withdrawn out of 7 trials

Success Rate

85.7%

-0.8% vs industry average

Late-Stage Pipeline

14%

1 trials in Phase 3/4

Results Transparency

17%

1 of 6 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 2

4(57.1%)

Phase 1

2(28.6%)

Phase 3

1(14.3%)

7Total

Phase 2(4)

Phase 1(2)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT02829996Phase 2Completed

Study of Fixed-Dose Combinations of Trabodenoson and Latanoprost in Adults With OHT or POAG

Role: lead

NCT01917383Phase 2Completed

A Phase II Study to Evaluate the Additivity of Trabodenoson to Latanoprost in Adults With Ocular Hypertension or Primary Open-Angle Glaucoma

Role: lead

NCT02565173Phase 3Completed

Study of Trabodenoson in Adults With Ocular Hypertension or Primary Open-angle Glaucoma

Role: lead

NCT00271167Phase 2Terminated

A Trial of INO-1001 in Patients Undergoing Heart Surgery That Involves Heart-lung Bypass

Role: lead

NCT01123785Phase 1Completed

A Dose-Escalation Study Designed to Evaluate the Tolerability, Safety, Pharmacokinetics (PK), and Efficacy of Chronic Topical Ocular Application of INO-8875 in Adults With Ocular Hypertension or Primary Open-Angle Glaucoma

Role: lead

NCT01123772Phase 1Completed

Phase I Dose-Escalation Study to Evaluate Tolerability, Safety & PK of INO-8875 in Healthy Older-Adult Volunteers

Role: lead

NCT00271765Phase 2Completed

A Study of INO-1001, an Intravenous PARP (Poly [ADP Ribose] Polymerase) Inhibitor in Acute Heart Attack Patients Undergoing Primary Percutaneous Coronary Intervention

Role: lead

All 7 trials loaded